Tag
In association with pharmaphorum, Tag discusses what pharmaceutical marketers can to do stay ahead of the evolving customer journey.
Watch Now
ICON
Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disorder affecting some 40,000 individuals in Europe at any time, causing 10,000 deaths each year. As with other age-related neurodegenerative diseases, the drug development field is littered with inconclusive or negative trials. Modifying Immune Response and Outcomes in ALS (MIROCALS) is an international European Union H2020-funded trial of low-dose interleukin-2 in motor neuron disease (MND)/ALS. It aims to break this impasse in the development of disease-modifying agents through novel trial design, incident (early post-diagnosis) recruitment, integration of biomarkers/transcriptomics and cohort stratification. Join this webinar to hear about an overview of the study in addition to a discussion of the challenges both anticipated and unanticipated in recruiting participants recently diagnosed with a rare, rapidly disabling and ultimately life-limiting condition.
Watch Now
The pandemic was a unique time in our industry where there was a perfect storm of need, money, collaboration, and trial patients all available in abundance. There was an atmosphere of all hands, and resources, on deck in the race to a COVID-19 vaccine.
Watch Now
Competency-based medical education (CBME) requires a vigorous and multidimensional assessment system. In order to successfully implement CBME, assessment processes must be continuous and frequent.
Watch Now